CineCast: How Insert-Editing Overcame Industry Dubiety, Pushback and Apprehension

 

On this episode of CineCast by Cinedeck, we are joined once again by Charles D’Autremont, CEO of Cinedeck, to discuss the innovation of insert-editing software in the world of digital media. If you haven’t listened to part one, start there to learn about D’Autremont’s early career and how the idea of insert-editing came to be. On part two today, we explored how cineX evolved into a working program, and the challenges of introducing this revolutionary software into production media workflows.

“Because we were editing files, there was initially pushback about… ‘How do we know you haven’t screwed up the file?’,” D’Autremont said of early naysayers.

Even now, he said, there are reluctant adopters still clinging to the idea that “a file is this inviolable object.” But as the cineX demonstrated its capabilities, editors began to change their minds.

“As soon as they saw it worked, they were totally psyched about it, and became great advocates,” D’Autremont said.

Today, D’Autremont said cineX is “…used for hundreds of thousands of hours worth of television…” But the journey to where cineX is today was not easy, and continues to overcome challenges as it must simultaneously remain cutting edge, as well as compatible with the past.

For the latest news, videos, and podcasts in the Software & Electronics Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!
Twitter – @TechMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More